TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03893214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality exposure for acrophobia
Description: The setting of the virtual reality is the Gasometer Oberhausen, Europe's largest disc-type gas container which is one of the most famous high buildings in the area. After a baseline phase, participants will undergo a gradual exposure. Participants will first look up to the building and then be guided upstairs to have an exposure phase on 11 floors. On the highest floor they will walk around a gallery. In the end, there will be a recovery phase.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: virtual reality exposure for acrophobia
Description: The setting of the virtual reality is the Gasometer Oberhausen, Europe's largest disc-type gas container which is one of the most famous high buildings in the area. After a baseline phase, participants will undergo a gradual exposure. Participants will first look up to the building and then be guided upstairs to have an exposure phase on 11 floors. On the highest floor they will walk around a gallery. In the end, there will be a recovery phase.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: movie
Description: Participants will watch a movie without height content for the same amount of time as the virtual reality exposure will need.
Study: NCT03434366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine and dexmedetomidine
Description: intranasal ketamine and dexmedetomidine for treatment for autism spectrum disorder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: intranasal ketamine for treatment for autism spectrum disorder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intranasal saline for treatment for autism spectrum disorder
Study: NCT00977561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: figitumumab
Description: Figitumumab (20 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (Or Carboplatin)
Description: Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide (100 mg/m2 IV on Days 1, 2 and 3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin (Or Carboplatin)
Description: Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
Study: NCT01873833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02039947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be provided as 0.5 mg and 2.0 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be provided as 0.5 mg and 2.0 mg tablets
Study: NCT03264950

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Elastography
Description: an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.~Similarly an acoustic window will be selected for the pancreas as well
Study: NCT00927082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
Study: NCT02475837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorapaxar sulfate
Description: The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.
Study: NCT02039947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be provided as 0.5 mg and 2.0 mg tablets
Study: NCT00644267

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: Telemedicine reporting of blood pressure, weight, physical activity

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Telemedicine
Description: Telemedicine reporting of blood pressure, weight, physical activity
Study: NCT00551356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro mix 25
Description: Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
Study: NCT02006654

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, matching placebo capsules, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine
Description: Once daily, encapsulated tablets, orally
Study: NCT03176199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Every 12 hours for control-released oxycodone (OxyContin®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Every 6 hours for immediate-released oxycodone (OxyNorm®)
Study: NCT02198144

Intervention type: OTHER
Group type: OTHER
Intervention: barbershop-based BP measurement
Description: BP Measurements and blood pressure reducing medication
Study: NCT03384043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Personal Assistant
Description: Electronic memory aids (e.g., pagers) are known to support memory for goals and intentions (prospective memory) in individuals with cognitive impairment. Smartphone technology has the potential to enhance the benefits of previous electronic memory aids because they can provide reminders not only at the correct time, but also at the correct location.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Intention
Description: Verbally specifying when and where one intends to complete a goal or action (prospective memory) is known to improve the likelihood of later completing that prospective memory. The implementation intention is the best known memory strategy for prospective memory in patients with mild cognitive impairment.
Study: NCT01420575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Decision Aid and Shared Decision Making Model
Description: Visual aid is a graph showing the average weight of patients who take olanzapine versus perphenazine over the course of 18 months. A script explaining the information on the graph, accompanies the graph. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
Study: NCT02823561

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garcinia mangostana

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Study: NCT00769405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given during surgery
Study: NCT01420575

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care is standard clinical discussion and advice from a psychiatrist. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
Study: NCT01874483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00769405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperthermia treatment
Description: Given intraperitoneally during surgery
Study: NCT01874483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 3
Study: NCT03364218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine
Description: Nebulized N-Acetyl Cysteine administered every 12 hours
Study: NCT03850106

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Indus810
Description: Active product
Study: NCT02523638

Intervention type: DRUG
Group type: OTHER
Intervention: Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
Description: Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
Study: NCT03846232

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02451735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video and Booklet
Description: Printed and DVD materials about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the control group response.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Factsheet
Description: Patient factsheet about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the intervention group response.
Study: NCT04149353

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant chemotherapy per the direction of the medical oncologist. Within four weeks after completion of chemotherapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery if they are still surgical candidates.
Study: NCT00945620

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ropivicaine
Description: 30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT04268511

Intervention type: PROCEDURE
Intervention: Caudal epidural block group
Description: The linear probe of ultrasound was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone. A 22 Gauge 50 mm echogenic block needle was advanced

Intervention type: PROCEDURE
Intervention: Pudendal nerve block group
Description: A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
Study: NCT00849472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin + cyclophosphamide
Description: 4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel + pazopanib
Description: 4 cycles of paclitaxel + pazopanib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: neoadjuvant surgery for breast cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib monotherapy
Description: 6 months of treatment with pazopanib monotherapy
Study: NCT00834938

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03193268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-blind RTC of PD patients
Description: The groups participate in observation for 5 weeks. Two groups take part in a motion therapy over the 5-week period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cycling
Description: Patients must undergo a daily exercise cycle of 1 hour during the intervention
Study: NCT02068599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-45070
Description: TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-45070
Description: TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
Study: NCT04041128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lynparza
Description: Lynparza taken orally at a dose of 300mg twice daily for 7 days
Study: NCT01428128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: IV; 0.005mg/kg. Infusion on Days -3, -2 and -1 of Chemo Cycles 2, 4, and 6 (if more than 4 cycles received).
Study: NCT04076215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stressogenic stimulus
Description: Participants will be exposed to an anxiety-provoking stimulus for 15-20 minutes, in a controlled setting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stressogenic stimulus
Description: Participants will be exposed to an anxiety-provoking stimulus for 15-20 minutes, in a controlled setting

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biobeat smart watch and adhesive biosensor patches.
Description: Physiological and biochemical measures will be obtained using the Biobeat smart watch and adhesive biosensor patches.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biobeat smart watch and adhesive biosensor patches.
Description: Physiological and biochemical measures will be obtained using the Biobeat smart watch and adhesive biosensor patches.
Study: NCT00680173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a and plus ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a and plus ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
Study: NCT02439619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TechCare
Description: The TechCare software is being developed specifically for use on a touch screen mobile phone. The mobile application will alert participants through notifications and ask a number of questions. Based on participant responses the app will provide a CBT based response to individuals or the service users preferred multimedia such as music, images and videos.
Study: NCT02478502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
Study: NCT01470807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: portable artificial pancreas system with CTR algorithms
Description: The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
Study: NCT01209468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: monobloc oral appliance
Description: one piece oral appliance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: twinblock oral appliance
Description: two-piece oral appliance
Study: NCT02913625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided retroclavicular block
Description: Ultrasound guided retroclavicular block for forearm or hand surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided infraclavicular block
Description: Ultrasound guided infraclavicular block for forearm or hand surgery
Study: NCT05343910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aroma massage
Description: The older adult participants in the experimental group were applied aroma massage through gentle movements with slight pressure for 15 min a day, five days a week for three weeks.
Study: NCT04459962

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breath Test & Cheek Swab
Description: Breath Sample and Cheek Swab of participants will be used for machine learning (NBT - Nanobiotechnology Biomarkers Tagging) system to develop a profile which can be used later on for Covid-19 Diagnosis.
Study: NCT02032953

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Travasol (amino acid injection)
Description: an amino acid supplementation infused intravenously containing essential and non-essential amino acids

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Travasol (amino acid injection)
Description: an amino acid supplementation infused intravenously containing essential and non-essential amino acids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg\*min. Ten minuts after starting the insulin, and when the the blood glucose is\<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg\*min. Ten minuts after starting the insulin, and when the the blood glucose is\<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg\*min. Ten minuts after starting the insulin, and when the the blood glucose is\<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.
Study: NCT00336362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Hydroxyurea: Subjects will be treated for one month with hydroxyurea at a starting dose of 10 mg/kg orally (closest approximation to 500 mg capsule, alternate day dosing, e.g. 500 alternating with 1000 to achieve 750 mg average daily dose), once daily, with a gradual dose escalation up to 20 mg/kg (in non-splenectomized patients) and up to 25 mg/kg (in splenectomized patients).~G-CSF: G-CSF will be administered subcutaneously. In general, G-CSF will be administered at 10μg/kg/day (5μg/kg on a twice a day schedule) for at least 4-5 days before leukapheresis and for 1-2 additional days during collections. For the splenectomized patients who are not receiving HU pretreatment, and for the splenectomized patients who receive HU pretreatment who have greater than or equal to 12,000 WBCs before G-CSF, G-CSF will start at a lower dose (for example, 1.5 or 2.5 µg/kg); the next doses will be adjusted by the Principal Investigator based on the observed degree of leukocytosis.
Study: NCT01104831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: cooled sleeve placed over fracture site.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Room temperature cuff
Description: sleeve with room temperature water placed over fracture site.